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Abstract
We summarize original research in the field of critical care
nephrology accepted or published in 2005 in Critical Care and,
when considered relevant or directly linked to this research, in
other journals. The articles have been grouped into four categories
to facilitate a rapid overview. First, physiopathology, epidemiology
and prognosis of acute renal failure (ARF): an extensive review and
some observational studies have been performed with the aim of
describing aspects of ARF physiopathology, precise epidemiology
and long-term outcomes. Second, several authors have performed
clinical trials utilizing a potential nephro-protective drug, fenoldo-
pam, with different results. Third, the issue of continuous renal
replacement therapies dose has been addressed in a small
prospective study and a large observational trial. And fourth,
alternative indications to extracorporeal treatment of ARF and
systemic inflammatory response syndrome have been explored by
three original clinical studies.
Introduction
During 2005, Critical Care accepted and published articles
of original research focused on critical care nephrology and
renal replacement therapy (RRT). These studies included
papers on epidemiology, prognosis and medical therapy of
acute renal failure (ARF), the issue of continuous RRT
(CRRT) dose and alternative indications to extracorporeal
therapies.
We present a review of these papers and other key articles
on critical care nephrology published in 2005.
Physiopathology, epidemiology and
prognosis of ARF
To assess changes in renal blood flow (RBF) in human and
experimental sepsis, and to identify determinants of RBF,
Langenberg and co workers [1] performed an electronic
database search and tried to identify experimental and human
studies of septic acute renal failure in which RBF was
measured. Surprisingly, they found that no human studies
measured RBF with suitably accurate direct methods. Where
it was measured in septic patients, however, RBF was
increased compared with normal. The authors concluded that
the impact of sepsis on RBF in humans is unknown. When
examined in experimental models of sepsis, RBF was
decreased in two-thirds of studies (62%) and unchanged or
increased in one-third (38%). Multivariate analysis suggested
that cardiac output might have a substantial effect on RBF
during experimental sepsis, such that, in the presence of a
decreased cardiac output, RBF is typically decreased,
whereas in the presence of a preserved or increased cardiac
output RBF is typically maintained or increased. This
extensive analysis introduces a provocative hypothesis in the
physiopathology of ARF: the traditional mechanism of
ischemic ARF in critically ill septic patients is put to
discussion and, if confirmed by specifically designed
experimental and human studies, it could provide new
important information about the prevention and therapy of
septic ARF.
The impact on mortality of severe ARF (sARF), defined as the
requirement for RRT with evidence of renal dysfunction
(serum creatinine >150 mmol/l) during intensive care unit
(ICU) admission, was examined by Bagshaw and co-authors
[2]. A survey was conducted over a period of 36 months
among an adult population of over 700,000 residents. sARF
occurred in 240 patients (11.0 per 100,000 population/year).
Rates were highest in males and older patients (≥65 years of
age). Risk factors for development of sARF included previous
heart disease, stroke, pulmonary disease, diabetes mellitus,
cancer, connective tissue disease, chronic renal dysfunction,
and alcoholism. The annual mortality rate was 7.3 per
100,000 residents with highest rates in males over 65 years.
The 28-day, 90-day, and 1-year case-fatality rates were 51%,
60%, and 64%, respectively. An increased number of co-
morbidities, the presence of liver disease, a higher
APACHE II score, septic shock, and the need for CRRT were
independently associated with death at 1 year. Renal recovery
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occurred in 78% (68/87) of survivors at 1 year, meaning that,
although the majority of patients with sARF will die, most
survivors will become independent from RRT within a year.
With a similar intention of determining the association
between outcome and different epidemiological parameters
(period prevalence of ARF, etiology, illness severity, and
clinical management of ARF), the Beginning and Ending
Supportive Therapy for the Kidney (BEST Kidney) Investi-
gators conducted a multinational, multicenter, prospective,
epidemiological survey of ARF in ICU patients [3] who were
either treated with RRT or fulfilled at least one of the
predefined criteria for ARF. Predefined ARF criteria were
oliguria, defined as urine output of less than 200 ml in
12 hours, and/or marked azotemia, defined as a blood urea
nitrogen level higher than 30 mmol/l. The data were collected
from September 2000 to December 2001 at 54 hospitals in
23 countries. Of 29,269 critically ill patients admitted during
the 16 month study period, 1,738 (5.7%) had ARF during
their ICU stay, including 1,260 (4.3%) who were treated with
RRT. Overall hospital mortality was 60.3%. The most
common contributing factor to ARF was septic shock
(47.5%). Approximately 30% of patients had preadmission
renal dysfunction. Of the survivors, 86.2% were independent
from dialysis at hospital discharge. Independent risk factors
for hospital mortality included use of vasopressors,
mechanical ventilation, septic shock, cardiogenic shock, and
hepatorenal syndrome.
From the findings of these studies we can reasonably
conclude that the prevalence of ARF among the ICU
population is between 5% and 6%, that more than 70% of
these patients require RRT, that hospital survival among ARF
patients is still disappointing (about 40%), and that renal
recovery among survivors is very high. A systematic literature
review [4] confirmed the suspicion that no evidence of a
substantial improvement in outcome from ARF over the past
50 years has been observed. The mortality rates remain
higher than 50%, despite new approaches to general
management, such as advanced monitoring, and despite new
available RRT machines and a trend to increased prescription
of dialytic dose. Another point that should be commented on
is the urgent need for a common definition of ARF, an
essential instrument in comparing different epidemiological
studies and for evaluating therapies during clinical trials [5].
Fenoldopam: a new medical approach to ARF?
If the outcome of critically ill ARF patients is still poor, the
issue of prevention and protection from this lethal condition
becomes a priority. Four randomized controlled and one
retrospective trial on fenoldopam utilization were published
between January 2005 and January 2006: in all cases this
relatively new drug was administered to prevent or treat
ARF in critically ill patients or in post cardio-surgical
patients, a specific population that is particularly prone to
develop ARF.
At present, evidence-based medicine dictates that there is no
place in clinical practice for dopamine infusion in the preven-
tion or treatment of ARF [6]. Fenoldopam, unlike dopamine,
stimulates only dopamine 1 (and not dopamine 2) receptors,
thus theoretically inducing greater vasodilation in the renal
medulla than in the cortex. Furthermore, fenoldopam has no α
or β adrenergic activity, properties that are believed to cause
arrhythmias and other adverse effects during dopamine
infusion.
Tumlin and co-workers [7] conducted a randomized placebo-
controlled trial in 155 patients with early acute tubular
necrosis with the hypothesis that administration of low-dose
fenoldopam (0.1 µg/kg/minute) would decrease the need for
dialysis therapy and/or incidence of death at 21 days.
Patients with a serum creatinine level increasing to 50%
greater than a normal baseline level (creatinine >133 mmol/l)
or a 25% increase greater than a baseline level greater than
1.5 mg/dL (133 mmol/l) during a single 24 hour period from
ICU admission were considered to have a diagnosis of early
acute tubular necrosis. The authors found a non-statistically
significant 11% absolute reduction in the primary end point.
Similarly, there was no difference in the incidence of dialysis
therapy between patients randomly assigned to fenoldopam
versus the placebo group. Finally, there was a non-statistically
significant trend to 21-day mortality decrease in the fenoldo-
pam group (fenoldopam, 13.8% versus placebo, 25.3%;
P = 0.068).
Morelli and co-workers [8] conducted a randomized placebo-
controlled trial in 300 septic patients with baseline serum
creatinine concentrations <150 mmol/l. The peculiar design
of this study considered as eligible patients all subjects with
sepsis but without signs of acute renal dysfunction, in order
to eventually obtain a prophylaxis from the occurrence of
ARF. Patients received a continuous low-dose infusion of
fenoldopam (0.09 µg/kg/minute) or placebo. The authors
observed that fenoldopam induced a significant reduction in
mild ARF incidence (creatinine concentrations >150 mmol/l
and <300 mmol/l), a non-significant trend to reduced severe
ARF (creatinine concentrations >300 mmol/L) incidence and
a non-significant difference in 28-day mortality with respect to
placebo.
Brienza and co-workers [9] randomized 100 adult critically ill
patients with early renal dysfunction (urine output ≤0.5 ml/kg
over a 6 hour period and/or serum creatinine concentration
≥1.5 mg/dL and ≤3.5 mg/dL) for whom ICU stay was lower
than 1 week. Patients were randomized to receive
2 µg/kg/minute  dopamine or 0.1 µg/kg/minute fenoldopam.
Drugs were administered as continuous infusion over a 4 day
period. Fenoldopam produced a more significant reduction in
creatinine values compared with dopamine after 2, 3, and
4 days of infusion. The maximum decrease in creatinine
compared with baseline was significantly greater in patients
who received fenoldopam. Total urinary output during drugPage 3 of 5
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infusion was not significantly different between groups.
Differences between the two groups in dialysis need and
mortality were not examined by the authors.
These three works share a similar low-dose infusion of
fenoldopam, which appears safe and free from hypotensive
effects. All authors designed the studies in order to
administer the drug at a very early stage after ICU admission.
All studies showed a positive effect on creatinine levels. None
of them was able to show significant effects on protection
from dialysis and mortality. These puzzling results must be
examined with care: the stage has been set for a large, phase
III, multicenter, randomized, placebo-controlled trial to test
renal-dose fenoldopam before its routine use in clinical
practice.
Two important studies in high-risk post cardiosurgical
patients were also conducted with the utilization of fenoldo-
pam as a nephro-protective drug.
Bove and co-workers [10] performed a prospective single-
center, randomized, double-blind trial with 80 patients under-
going cardiac surgery. Patients received either fenoldopam at
0.05 µg/kg/minute or dopamine at 2.5 µg/kg/minute after the
induction of anesthesia for a 24 hour period. All these
patients were at high risk of perioperative renal dysfunction
as indicated by Continuous Improvement in Cardiac Surgery
Program score >10. The primary end point was defined as
25% creatinine increase from baseline levels after cardiac
surgery. No difference in outcome was observed between the
two groups. Incidence of ARF was similar; peak
postoperative serum creatinine level, intensive care unit and
hospital stay, and mortality were also similar in the two
groups. The randomization was interrupted at an interim
analysis for lack of efficacy of the drug.
A small retrospective study [11] recently suggested a
positive effect of fenoldopam on diuresis in 25 neonates who
were failing to achieve an adequate negative fluid balance
despite conventional diuretic therapy after high risk cardiac
surgery and cardiopulmonary bypass. The particular setting of
this paper and its initial results, however, deserve further data
collection in order to draw any definitive conclusion.
The dose of dialysis
It is still unclear whether a correlation between dialysis
treatment dose and outcome exists and no consensus has
been reached on how much treatment is adequate [12]. A
Microsoft Excel based software called ‘Adequacy Calculator
for ARF’ has been described and tested: it is a simple and
manageable tool designed to prescribe RRT dose and to
collect information about the quantity of delivered treatments
[13]. Once the required parameters are entered, it calculates
urea clearance and fractional clearance, spKt/V (sp = single
pool, K = clearance, t = time, V = urea volume of distribution)
for each CRRT modality. Data from 106 consecutive CRRT
treatments administered to 30 critically ill patients with ARF
were collected. Kt/V has not yet been validated as a marker
of adequacy in patients with ARF, but it seems that a
rationale exists for its use in continuous therapies. We found
that the Adequacy Calculator was able to predict the
delivered urea clearance accurately: the value of clearance
predicted by the calculator was strongly correlated with the
value obtained from determination on blood and dialysate,
regardless of which CRRT modality was selected. The
correlation between prediction and effective delivery
remained high over a time range of 24 hours and within a
value of spKt/V of 1.4, which approaches the target of
35 ml/kg/h, when delivered for 24 hours [14]. This tool might
help clinicians to correlate different dose prescriptions with
different clinical outcomes.
The DOse REsponse Multicenter International (DO-RE-MI)
collaborative initiative [15] is a multicenter observational
study that aims to describe current practices of RRT in all
ICU patients admitted to ICUs who are in need of RRT. It will
also provide a center-based collection of data that will be
useful for monitoring all aspects of extracorporeal support,
such as incidence, frequency, duration, reasons to start and
stop RRT, downtime, and, above all, eventual correlation
between delivered dose and outcome. All data are entered in
electronic case report forms that are available via the internet
[16]. The study is still ongoing, and at interim analysis 199
patients (141 male and 58 female with a mean age of 56.7
and 61.5 years, respectively) from 42 centers in 5 countries
(Spain, Italy, Germany, Portugal and France) have been
recruited. Large variability in the delivered dose is
anticipated and the study should hopefully show whether
and to what extent RRT dose impacts on mortality and
hemodynamics.
Alternative indications to extracorporeal
treatments
The sepsis syndrome is the most common cause of ARF and
multiple organ dysfunction in critically ill subjects and
continues to have high mortality. Normal immune homeostasis
is interrupted by a complex storm of inflammatory mediators
responsible for the deleterious effects. Extracorporeal blood
purification therapy can confer benefits in sepsis by proven
non-specific removal of these mediators (pro- or anti-
inflammatory), and provide a rationale to treat this syndrome
[17]. High volume hemofiltration (HVHF) has had the most
dramatic effects, providing benefits in hemodynamics,
enabling reduction of vasopressor doses and improving
survival [18]. Pulse HVHF (PHVHF) is a different approach
that may offer the most efficient results: it consists of a daily
schedule of 6 to 8 hours at a pre-dilution replacement rate of
85 ml/kg/h followed by standard CVVH at a standard dose of
35 ml/kg/h [19]. In this study, 15 patients were treated, with
no treatment prematurely discontinued [19]. Haemodynamics
were improved by PHVHF, allowing a significant reduction in
noradrenaline dose during and at the end of the PHVHF
Available online http://ccforum.com/content/10/4/226session; this reduction was maintained at 6 and 12 hours
after pulse treatment. There was also an improvement in
systolic blood pressure. There were no changes in
temperature, cardiac index, oxygenation, arterial pH or urine
output during the period of observation. The mean daily
spKt/V was 1.92. Predicted mortality rates were 72% (based
on APACHE II score) and 68% (based on SAPS II score),
and the observed 28-day mortality was 47%.
Another important randomized controlled trial of extra-
corporeal purification techniques evaluated the polymyxin B-
immobilized (PMX) endotoxin removal hemoperfusion
cartridge [20], which has been shown to remove endotoxin in
preclinical and open-label clinical studies. In this study, 36
postsurgical patients admitted to 6 European ICUs with
severe sepsis or septic shock secondary to intra-abdominal
infection were randomized to PMX treatment of 2 hours or
standard therapy. No statistically significant differences in the
change of endotoxin and interleukin-6 levels from baseline to
24 hours after treatment between the two groups were
shown. Patients treated with PMX demonstrated significant
increases in cardiac index, left ventricular stroke work index,
and oxygen delivery index compared with controls. The need
for CRRT after study entry was reduced in the PMX group.
There was no significant difference between the groups with
regards to organ dysfunction, as assessed by the Sequential
Organ Failure Assessment scores, from day 0 (baseline) to
day 6.
A French group [21] randomized 61 critically ill patients into
three hemofiltration treatment groups in order to evaluate the
effect of isovolumic HVHF alone or combined with mild
hypothermia on survival after out-of-hospital cardiac arrest
with initial ventricular fibrillation or asystole. The three groups
were control, HVHF (200 ml/kg/h over 8 hours) or HVHF with
mild hypothermia (32°C for 24 hours) induced by cooling the
hemofiltration substitution fluid. The primary end point was
survival with a follow-up time of six months. The effect of
hemofiltration on death by intractable shock was the
secondary end point. After adjustment for baseline
characteristics of cardiac arrest, hemofiltration (with or
without hypothermia) was associated with improved survival.
Compared to the control group, the relative risk of death by
intractable shock was 0.29 in the hemofiltration-hypothermia
group and 0.21 in the hemofiltration group.
These three studies show a beneficial effect of extracorporeal
blood purification therapy on hemodyanmics of patients with
systemic inflammatory syndrome from different causes:
despite intriguing results and promising improvement in
patient outcome, the limited statistical power of these trials
still limits the use of extracorporeal blood purification therapy
to the strict boundaries of clinical research.
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